Baseline Circulating Tumour Dna and Total Metabolic Tumour Volume as Early Outcome Predictors in Aggressive B‐cell Lymphoma. A Real Life Prospective 112‐patient Cohort

Abstract

As of March 2021, analysis of 92 patients had been finalized.Patients older than 60 years had a significantly lower TCR repertoire diversity compared to younger (p = 0.03, Wilcoxon rank sum test).There was no association between lymphoma subtype and TCR repertoire diversity. In a Kaplan-Meier survival analysis we found a trend towards longer overall survival in patients with high TCR repertoire diversity (Figure 1). Detailed profiling of the TCR repertoire coupled with long term follow-up of patients undergoing ASCT may provide novel information regarding the impact of the patient's own adaptive immune response on treatment efficacy. A dysfunctional T-cell repertoire can furthermore have implications for selection of patients to undergo cellular therapies (ie. ASCT or CAR T-cell treatment) in contrast to non-cellular therapies (i.e. bispecific antibodies, small molecule inhibitors). Full analysis of all 288 patients and correlation with post-transplant infections, transfusions and secondary cancers are ongoing and will be presented at the 16-ICML.